Annovis Bio, Inc. (ANVS) Financials

ANVS Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 16.2 million 13.1 million
Dec. 31, 2025 21.1 million 4.2 million
Sept. 30, 2025 17.2 million 4.0 million
June 30, 2025 21.5 million 3.1 million

ANVS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -9.0 billion 182.8 million
Dec. 31, 2025 -8.9 million 356524
Sept. 30, 2025 -3.5 million 444647
June 30, 2025 -5.1 million 496618

ANVS Net Income

No data available :(

ANVS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 14.2 million - -
Dec. 31, 2025 19.5 million - -
Sept. 30, 2025 15.3 million - -
June 30, 2025 17.1 million - -

ANVS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 27.8 million
Dec. 31, 2025 24.8 million
Sept. 30, 2025 19.7 million
June 30, 2025 19.5 million

ANVS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 16.7 billion 1.3 billion -
Dec. 31, 2025 - 8.8 million 955151 -
Sept. 30, 2025 5 6.3 million 1.1 million -
June 30, 2025 - 5.2 million 1.1 million -

ANVS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - -
Dec. 31, 2025 - -
Sept. 30, 2025 - -
June 30, 2025 - -

ANVS

Price: $1.75

52 week price:
1.54
5.50

Earnings Per Share: -1.71 USD

Exchange: NYQ

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 103127

Market Capitalization: 37.2 million

Links: